Thursday - April 30, 2026
Ultomiris Demonstrated Statistically Significant and Clinically Meaningful Reduction of Proteinuria in Adults With Immunoglobulin A Nephropathy in I CAN Phase III Trial
April 22, 2026
WILMINGTON, Delaware, April 22 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

ULTOMIRIS(R) (ravulizumab-cwvz) demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with immunoglobulin A nephropathy in I CAN Phase III trial

ULTOMIRIS delivered rapid reduction in proteinuria as early as week 10

Results show potential for terminal C5 complement inhibition with ULT . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products